Consensus and controversies regarding the treatment of rhabdomyosarcoma
Pediatric Blood & Cancer2017Vol. 65(2)
Citations Over TimeTop 10% of 2017 papers
Scott C. Borinstein, Diana Steppan, Masanori Hayashi, David M. Loeb, Michael S. Isakoff, Odion Binitie, Andrew S. Brohl, Julia A. Bridge, Mark J. Stavas, Eric T. Shinohara, William H. Meyer, Damon R. Reed, Lars M. Wagner
Abstract
Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.
Related Papers
- → Genetic Modeling of Human Rhabdomyosarcoma(2005)84 cited
- → Lower eyelid rhabdomyosarcoma in a 3-month-old infant(2010)5 cited
- → Soft-Tissue Sarcomas in Childhood. A Study of 262 Cases Including 169 Cases of Rhabdomyosarcoma*(1985)18 cited
- [Treatment results for rhabdomyosarcoma in children].(1997)
- → Maintenance Low-Dose Chemotherapy in High-Risk Rhabdomyosarcoma(2018)